USE OF AN EXTRACELLULAR ADHERENCE PROTEIN FOR THE MANUFACTURE OF AN ANTIINFLAMMATORY DRUG

Details for Australian Patent Application No. 2002347742 (hide)

Owner BIOSTAPRO AB

Inventors FLOCK, Jan-Ingmar; HERRMANN, Mathias; PREISSNER, Klaus, T; CHAVAKIS, Triantafyllos

Pub. Number AU-A-2002347742

PCT Number PCT/SE02/02075

PCT Pub. Number WO2003/041726

Priority 60/331,456 16.11.01 US; 60/331,782 21.11.01 US; 0103831-4 16.11.01 SE

Filing date 14 November 2002

Wipo publication date 26 May 2003

International Classifications

A61K 035/74 Medicinal preparations containing material or reaction products thereof with undetermined constitution

A61P 029/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

A61P 035/00 Antineoplastic agents

Event Publications

13 March 2003 Complete Application Filed

  Priority application(s): 60/331,456 16.11.01 US; 60/331,782 21.11.01 US; 0103831-4 16.11.01 SE

24 July 2003 Application Open to Public Inspection

  Published as AU-A-2002347742

5 August 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002347743-A METHOD OF VERIFYING IDPAPERS AND THE LIKE, AND A METHOD TO USE INFORMATION CARRIED BY AN ID-DOCUMENT STORED IN A DATA BASE FOR VERIFYING PURCHASES BY CREDIT OR BANK CARDS

2002347741-N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation